Compare AbbVie Inc (ABBV) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? AbbVie Inc trades at $247.82 (market cap $441.94B), while iShares Core MSCI Emerging Markets ETF trades at $80.89. The key difference: AbbVie Inc pays a 2.77% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals.
| ABBV | IEMG | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $263.58 | $86.00 |
52-Week Low | $197.38 | $61.76 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
IEMG trades at $81.10, up 1.93% with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% trailing returns but faces elevated volatility. Recent news highlights IEMG's 40% technology weighting and AI exposure in emerging markets, though some analysts caution about concentration risks after significant gains.
The outlook remains positive given attractive emerging market valuations and AI-driven growth potential, but investors should monitor volatility and geopolitical risks. The ETF's low 0.09% expense ratio and diversification across 2,700 stocks provide cost-effective exposure to developing economies with superior dividend growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
